Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-12-2019 | Magnetic Resonance Imaging | Review Article

Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer’s disease

Authors: Delphine Boche, Alexander Gerhard, Elena Rodriguez-Vieitez, on behalf of the MINC Faculty

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 13/2019

Abstract

Neuroinflammation, as defined by the activation of microglia and astrocytes, has emerged in the last years as a key element of the pathogenesis of neurodegenerative diseases based on genetic findings and preclinical and human studies. This has raised the need for new methodologies to assess and follow glial activation in patients, prompting the development of PET ligands for molecular imaging of glial cells and novel structural MRI and DTI tools leading to a multimodal approach. The present review describes the recent advancements in microglia and astrocyte biology in the context of health, ageing, and Alzheimer’s disease, the most common dementia worldwide. The review further delves in molecular imaging discussing the challenges associated with past and present targets, including conflicting findings, and finally, presenting novel methodologies currently explored to improve our in vivo knowledge of the neuroinflammatory patterns in Alzheimer’s disease. With glial cell activation as a potential therapeutic target in neurodegenerative diseases, the translational research between cell biologists, chemists, physicists, radiologists, and neurologists should be strengthened.

Available only for authorised users

Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405. https://doi.org/10.1016/S1474-4422(15)70016-5.CrossRefPubMedPubMedCentral

Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer’s disease. Nat Immunol. 2015;16(3):229–36. https://doi.org/10.1038/ni.3102.CrossRefPubMed

Vellas B, Bain LJ, Touchon J, Aisen PS. Advancing Alzheimer’s disease treatment: lessons from CTAD 2018. J Prev Alzheimers Dis. 2019;6(3):198–203. https://doi.org/10.14283/jpad.2019.11.CrossRefPubMed

Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019. https://doi.org/10.1001/jamaneurol.2019.1424.CrossRefPubMedPubMedCentral

Leyns CEG, Holtzman DM. Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener. 2017;12(1):50. https://doi.org/10.1186/s13024-017-0192-x.CrossRefPubMedPubMedCentral

Felsky D, Roostaei T, Nho K, Risacher SL, Bradshaw EM, Petyuk V, et al. Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. Nat Commun. 2019;10(1):409. https://doi.org/10.1038/s41467-018-08279-3.CrossRefPubMedPubMedCentral

Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330(6005):841–5 science.1194637.CrossRefPubMedPubMedCentral

Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity. 2013;38(4):792–804. https://doi.org/10.1016/j.immuni.2013.04.004.CrossRefPubMed

Bruttger J, Karram K, Wortge S, Regen T, Marini F, Hoppmann N, et al. Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. Immunity. 2015;43(1):92–106. https://doi.org/10.1016/j.immuni.2015.06.012.CrossRefPubMed

10.

Askew K, Li K, Olmos-Alonso A, Garcia-Moreno F, Liang Y, Richardson P, et al. Coupled proliferation and apoptosis maintain the rapid turnover of microglia in the adult brain. Cell Rep. 2017;18(2):391–405. https://doi.org/10.1016/j.celrep.2016.12.041.CrossRefPubMedPubMedCentral

11.

Reu P, Khosravi A, Bernard S, Mold JE, Salehpour M, Alkass K, et al. The lifespan and turnover of microglia in the human brain. Cell Rep. 2017;20(4):779–84. https://doi.org/10.1016/j.celrep.2017.07.004.CrossRefPubMedPubMedCentral

12.

Dennis CV, Suh LS, Rodriguez ML, Kril JJ, Sutherland GT. Human adult neurogenesis across the ages: an immunohistochemical study. Neuropathol Appl Neurobiol. 2016;42(7):621–38. https://doi.org/10.1111/nan.12337.CrossRefPubMedPubMedCentral

13.

Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17(1):131–43. https://doi.org/10.1038/nn.3599.CrossRefPubMed

14.

Minett T, Classey J, Matthews FE, Fahrenhold M, Taga M, Brayne C, et al. Microglial immunophenotype in dementia with Alzheimer’s pathology. J Neuroinflammation. 2016;13(1):135–45. https://doi.org/10.1186/s12974-016-0601-z.CrossRefPubMedPubMedCentral

15.

Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell. 2017;169(7):1276–90.e17. https://doi.org/10.1016/j.cell.2017.05.018.CrossRefPubMed

16.

Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47(3):566–81.e9. https://doi.org/10.1016/j.immuni.2017.08.008.CrossRefPubMedPubMedCentral

17.

Cribbs DH, Berchtold NC, Perreau V, Coleman PD, Rogers J, Tenner AJ, et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflammation. 2012;9:179–97 1742–2094–9-179.CrossRefPubMedPubMedCentral

18.

Norden DM, Godbout JP. Microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol. 2013;39(1):19–34. https://doi.org/10.1111/j.1365-2990.2012.01306.x.CrossRefPubMedPubMedCentral

19.

Rakic S, Hung YMA, Smith M, So D, Tayler HM, Varney W, et al. Systemic infection modifies the neuroinflammatory response in late stage Alzheimer’s disease. Acta Neuropathol Commun. 2018;6(1):88. https://doi.org/10.1186/s40478-018-0592-3.CrossRefPubMedPubMedCentral

20.

Mittelbronn M, Dietz K, Schluesener HJ, Meyermann R. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol. 2001;101(3):249–55. https://doi.org/10.1007/s004010000284.CrossRefPubMed

21.

Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308(5726):1314–8.CrossRefPubMed

22.

Squarzoni P, Oller G, Hoeffel G, Pont-Lezica L, Rostaing P, Low D, et al. Microglia modulate wiring of the embryonic forebrain. Cell Rep. 2014;8(5):1271–9. https://doi.org/10.1016/j.celrep.2014.07.042.CrossRefPubMed

23.

Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333(6048):1456–8. https://doi.org/10.1126/science.1202529.CrossRefPubMed

24.

Cunningham CL, Martinez-Cerdeno V, Noctor SC. Microglia regulate the number of neural precursor cells in the developing cerebral cortex. J Neurosci. 2013;33(10):4216–33. https://doi.org/10.1523/JNEUROSCI.3441-12.2013.CrossRefPubMedPubMedCentral

25.

Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci. 2009;29(13):3974–80. https://doi.org/10.1523/JNEUROSCI.4363-08.2009.CrossRefPubMedPubMedCentral

26.

Tremblay ME, Lowery RL, Majewska AK. Microglial interactions with synapses are modulated by visual experience. PLoS Biol. 2010;8(11):e1000527. https://doi.org/10.1371/journal.pbio.1000527.CrossRefPubMedPubMedCentral

27.

Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16(12):1896–905. https://doi.org/10.1038/nn.3554.CrossRefPubMedPubMedCentral

28.

Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–217. https://doi.org/10.1016/j.cell.2013.05.039.CrossRefPubMedPubMedCentral

29.

Lopez-Gonzalez I, Schluter A, Aso E, Garcia-Esparcia P, Ansoleaga B, LLorens F, et al. Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice: correlations with plaques, tangles, and oligomeric species. J Neuropathol Exp Neurol. 2015;74(4):319–44. https://doi.org/10.1097/NEN.0000000000000176.CrossRefPubMed

30.

Davies DS, Ma J, Jegathees T, Goldsbury C. Microglia show altered morphology and reduced arborization in human brain during aging and Alzheimer’s disease. Brain Pathol. 2016. https://doi.org/10.1111/bpa.12456.CrossRefPubMedPubMedCentral

31.

Streit WJ. Microglial senescence: does the brain’s immune system have an expiration date? Trends Neurosci. 2006;29(9):506–10.CrossRefPubMed

32.

Olah M, Patrick E, Villani AC, Xu J, White CC, Ryan KJ, et al. A transcriptomic atlas of aged human microglia. Nat Commun. 2018;9(1):539. https://doi.org/10.1038/s41467-018-02926-5.CrossRefPubMedPubMedCentral

33.

Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol. 2014;10(4):217–24. https://doi.org/10.1038/nrneurol.2014.38.CrossRefPubMed

34.

Neher JJ, Cunningham C. Priming microglia for innate immune memory in the brain. Trends Immunol. 2019. https://doi.org/10.1016/j.it.2019.02.001.CrossRefPubMed

35.

Wendeln AC, Degenhardt K, Kaurani L, Gertig M, Ulas T, Jain G, et al. Innate immune memory in the brain shapes neurological disease hallmarks. Nature. 2018;556(7701):332–8. https://doi.org/10.1038/s41586-018-0023-4.CrossRefPubMedPubMedCentral

36.

Akiyoshi R, Wake H, Kato D, Horiuchi H, Ono R, Ikegami A et al. Microglia enhance synapse activity to promote local network synchronization. eNeuro. 2018;5(5). doi:https://doi.org/10.1523/eneuro.0088-18.2018.CrossRefPubMedPubMedCentral

37.

Sudduth TL, Schmitt FA, Nelson PT, Wilcock DM. Neuroinflammatory phenotype in early Alzheimer’s disease. Neurobiol Aging. 2013;34(4):1051–9. https://doi.org/10.1016/j.neurobiolaging.2012.09.012.CrossRefPubMed

38.

Boche D, Perry VH, Nicoll JA. Activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol. 2013;39(1):3–18. https://doi.org/10.1111/nan.12011.CrossRefPubMed

39.

Albrecht DS, Granziera C, Hooker JM, Loggia ML. In Vivo imaging of human neuroinflammation. ACS Chem Neurosci. 2016;7(4):470–83. https://doi.org/10.1021/acschemneuro.6b00056.CrossRefPubMed

40.

Cosenza-Nashat M, Zhao ML, Suh HS, Morgan J, Natividad R, Morgello S, et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol. 2009;35(3):306–28. https://doi.org/10.1111/j.1365-2990.2008.01006.x.CrossRefPubMed

41.

Lavisse S, Guillermier M, Herard AS, Petit F, Delahaye M, Van Camp N, et al. Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci. 2012;32(32):10809–18. https://doi.org/10.1523/JNEUROSCI.1487-12.2012.CrossRefPubMedPubMedCentral

42.

Narayanaswami V, Dahl K, Bernard-Gauthier V, Josephson L, Cumming P, Vasdev N. Emerging PET radiotracers and targets for imaging of neuroinflammation in neurodegenerative diseases: outlook beyond TSPO. Mol Imaging. 2018;17:1536012118792317. https://doi.org/10.1177/1536012118792317.CrossRefPubMedPubMedCentral

43.

Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358(9280):461–7.CrossRefPubMed

44.

Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, et al. Microglia, amyloid, and cognition in Alzheimer’s disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008;32(3):412–9. https://doi.org/10.1016/j.nbd.2008.08.001.CrossRefPubMed

45.

Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One. 2010;5(11):e13950. https://doi.org/10.1371/journal.pone.0013950.CrossRefPubMedPubMedCentral

46.

Yokokura M, Mori N, Yagi S, Yoshikawa E, Kikuchi M, Yoshihara Y, et al. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2011;38(2):343–51. https://doi.org/10.1007/s00259-010-1612-0.CrossRefPubMed

47.

Yasuno F, Ota M, Kosaka J, Ito H, Higuchi M, Doronbekov TK, et al. Increased binding of peripheral benzodiazepine receptor in Alzheimer’s disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry. 2008;64(10):835–41. https://doi.org/10.1016/j.biopsych.2008.04.021.CrossRefPubMed

48.

Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 2009;72(1):56–62. https://doi.org/10.1212/01.wnl.0000338622.27876.0d.CrossRefPubMedPubMedCentral

49.

Parbo P, Ismail R, Hansen KV, Amidi A, Marup FH, Gottrup H, et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease. Brain. 2017;140(7):2002–11. https://doi.org/10.1093/brain/awx120.CrossRefPubMed

50.

Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, et al. Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol. 2009;66(1):60–7. https://doi.org/10.1001/archneurol.2008.511.CrossRefPubMedPubMedCentral

51.

Schuitemaker A, Kropholler MA, Boellaard R, van der Flier WM, Kloet RW, van der Doef TF, et al. Microglial activation in Alzheimer’s disease: an (R)-[(11)C]PK11195 positron emission tomography study. Neurobiol Aging. 2012. https://doi.org/10.1016/j.neurobiolaging.2012.04.021.CrossRefPubMed

52.

Hazell AS, Desjardins P, Butterworth RF. Chronic exposure of rat primary astrocyte cultures to manganese results in increased binding sites for the ‘peripheral-type’ benzodiazepine receptor ligand 3H-PK 11195. Neurosci Lett. 1999;271(1):5–8.CrossRefPubMed

53.

Venneti S, Wang G, Nguyen J, Wiley CA. The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders. J Neuropathol Exp Neurol. 2008;67(10):1001–10. https://doi.org/10.1097/NEN.0b013e318188b204.CrossRefPubMed

54.

Venneti S, Lopresti BJ, Wiley CA. Molecular imaging of microglia/macrophages in the brain. Glia. 2012. https://doi.org/10.1002/glia.22357.CrossRefPubMedPubMedCentral

55.

Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nuclear Med : official publication, Society of Nuclear Medicine. 2007;48(1):158–67.

56.

Chauveau F, Boutin H, Van Camp N, Dolle F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35(12):2304–19. https://doi.org/10.1007/s00259-008-0908-9.CrossRefPubMed

57.

Owen DR, Howell OW, Tang SP, Wells LA, Bennacef I, Bergstrom M, et al. Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab. 2010;30(9):1608–18. https://doi.org/10.1038/jcbfm.2010.63.CrossRefPubMedPubMedCentral

58.

Owen DR, Gunn RN, Rabiner EA, Bennacef I, Fujita M, Kreisl WC, et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nuclear Med : official publication, Society of Nuclear Medicine. 2011;52(1):24–32. https://doi.org/10.2967/jnumed.110.079459.CrossRef

59.

Yasuno F, Kosaka J, Ota M, Higuchi M, Ito H, Fujimura Y, et al. Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [(11)C]DAA1106. Psychiatry Res. 2012. https://doi.org/10.1016/j.pscychresns.2011.08.013.CrossRefPubMed

60.

Kreisl WC, Lyoo CH, McGwier M, Snow J, Jenko KJ, Kimura N, et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease. Brain. 2013;136(Pt 7):2228–38. https://doi.org/10.1093/brain/awt145.CrossRefPubMedPubMedCentral

61.

Hamelin L, Lagarde J, Dorothee G, Leroy C, Labit M, Comley RA, et al. Early and protective microglial activation in Alzheimer’s disease: a prospective study using 18F-DPA-714 PET imaging. Brain. 2016;139(Pt 4):1252–64. https://doi.org/10.1093/brain/aww017.CrossRefPubMed

62.

Hamelin L, Lagarde J, Dorothee G, Potier MC, Corlier F, Kuhnast B, et al. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer’s disease. Brain. 2018;141(6):1855–70. https://doi.org/10.1093/brain/awy079.CrossRefPubMed

63.

Ahmad R, Postnov A, Bormans G, Versijpt J, Vandenbulcke M, Van Laere K. Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2016. https://doi.org/10.1007/s00259-016-3457-7.CrossRefPubMed

64.

Van Weehaeghe D, Koole M, Schmidt ME, Deman S, Jacobs AH, Souche E, et al. [(11)C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson’s disease and healthy volunteers. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04369-6.CrossRefPubMed

65.

Horti AG, Naik R, Foss CA, Minn I, Misheneva V, Du Y, et al. PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci U S A. 2019;116(5):1686–91. https://doi.org/10.1073/pnas.1812155116.CrossRefPubMedPubMedCentral

66.

von Bartheld CS, Bahney J, Herculano-Houzel S. The search for true numbers of neurons and glial cells in the human brain: a review of 150 years of cell counting. J Comp Neurol. 2016;524(18):3865–95. https://doi.org/10.1002/cne.24040.CrossRef

67.

Oberheim NA, Takano T, Han X, He W, Lin JH, Wang F, et al. Uniquely hominid features of adult human astrocytes. J Neurosci. 2009;29(10):3276–87. https://doi.org/10.1523/jneurosci.4707-08.2009.CrossRefPubMedPubMedCentral

68.

Vasile F, Dossi E, Rouach N. Human astrocytes: structure and functions in the healthy brain. Brain Struct Funct. 2017;222(5):2017–29. https://doi.org/10.1007/s00429-017-1383-5.CrossRefPubMedPubMedCentral

69.

Farhy-Tselnicker I, Allen NJ. Astrocytes, neurons, synapses: a tripartite view on cortical circuit development. Neural Dev. 2018;13(1):7. https://doi.org/10.1186/s13064-018-0104-y.CrossRefPubMedPubMedCentral

70.

Santello M, Toni N, Volterra A. Astrocyte function from information processing to cognition and cognitive impairment. Nat Neurosci. 2019;22(2):154–66. https://doi.org/10.1038/s41593-018-0325-8.CrossRefPubMed

71.

Prebil M, Jensen J, Zorec R, Kreft M. Astrocytes and energy metabolism. Arch Physiol Biochem. 2011;117(2):64–9. https://doi.org/10.3109/13813455.2010.539616.CrossRefPubMed

72.

Mishra A, Reynolds JP, Chen Y, Gourine AV, Rusakov DA, Attwell D. Astrocytes mediate neurovascular signaling to capillary pericytes but not to arterioles. Nat Neurosci. 2016;19(12):1619–27. https://doi.org/10.1038/nn.4428.CrossRefPubMedPubMedCentral

73.

Brancaccio M, Edwards MD, Patton AP, Smyllie NJ, Chesham JE, Maywood ES, et al. Cell-autonomous clock of astrocytes drives circadian behavior in mammals. Science. 2019;363(6423):187–92. https://doi.org/10.1126/science.aat4104.CrossRefPubMedPubMedCentral

74.

Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7–35. https://doi.org/10.1007/s00401-009-0619-8.CrossRefPubMed

75.

Szu JI, Binder DK. The role of astrocytic aquaporin-4 in synaptic plasticity and learning and memory. Front Integr Neurosci. 2016;10:8. https://doi.org/10.3389/fnint.2016.00008.CrossRefPubMedPubMedCentral

76.

Sosunov AA, Wu X, Tsankova NM, Guilfoyle E, McKhann GM 2nd, Goldman JE. Phenotypic heterogeneity and plasticity of isocortical and hippocampal astrocytes in the human brain. J Neurosci. 2014;34(6):2285–98. https://doi.org/10.1523/jneurosci.4037-13.2014.CrossRefPubMedPubMedCentral

77.

John Lin CC, Yu K, Hatcher A, Huang TW, Lee HK, Carlson J, et al. Identification of diverse astrocyte populations and their malignant analogs. Nat Neurosci. 2017;20(3):396–405. https://doi.org/10.1038/nn.4493.CrossRefPubMed

78.

Jyothi HJ, Vidyadhara DJ, Mahadevan A, Philip M, Parmar SK, Manohari SG, et al. Aging causes morphological alterations in astrocytes and microglia in human substantia nigra pars compacta. Neurobiol Aging. 2015;36(12):3321–33. https://doi.org/10.1016/j.neurobiolaging.2015.08.024.CrossRefPubMed

79.

Clarke LE, Liddelow SA, Chakraborty C, Munch AE, Heiman M, Barres BA. Normal aging induces A1-like astrocyte reactivity. Proc Natl Acad Sci U S A. 2018;115(8):E1896–e905. https://doi.org/10.1073/pnas.1800165115.CrossRefPubMedPubMedCentral

80.

Goodall EF, Wang C, Simpson JE, Baker DJ, Drew DR, Heath PR, et al. Age-associated changes in the blood-brain barrier: comparative studies in human and mouse. Neuropathol Appl Neurobiol. 2018;44(3):328–40. https://doi.org/10.1111/nan.12408.CrossRefPubMed

81.

Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, et al. Genomic analysis of reactive astrogliosis. J Neurosci. 2012;32(18):6391–410. https://doi.org/10.1523/jneurosci.6221-11.2012.CrossRefPubMedPubMedCentral

82.

Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481–7. https://doi.org/10.1038/nature21029.CrossRefPubMedPubMedCentral

83.

Sofroniew MV. Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry. 2014;20(2):160–72. https://doi.org/10.1177/1073858413504466.CrossRef

84.

Thal DR. The role of astrocytes in amyloid beta-protein toxicity and clearance. Exp Neurol. 2012;236(1):1–5. https://doi.org/10.1016/j.expneurol.2012.04.021.CrossRefPubMed

85.

Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med. 2003;9(4):453–7. https://doi.org/10.1038/nm838.CrossRefPubMed

86.

Allaman I, Gavillet M, Belanger M, Laroche T, Viertl D, Lashuel HA, et al. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J Neurosci. 2010;30(9):3326–38. https://doi.org/10.1523/JNEUROSCI.5098-09.2010.CrossRefPubMedPubMedCentral

87.

Song W, Zhou LJ, Zheng SX, Zhu XZ. Amyloid-beta 25-35 peptide induces expression of monoamine oxidase B in cultured rat astrocytes. Acta Pharmacol Sin. 2000;21(6):557–63.PubMed

88.

Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease. Nat Med. 2014;20(8):886–96. https://doi.org/10.1038/nm.3639.CrossRefPubMedPubMedCentral

89.

Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989;24(3):173–82.CrossRefPubMed

90.

Serrano-Pozo A, Muzikansky A, Gomez-Isla T, Growdon JH, Betensky RA, Frosch MP, et al. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol. 2013;72(6):462–71. https://doi.org/10.1097/NEN.0b013e3182933788.CrossRefPubMed

91.

Pike CJ, Cummings BJ, Cotman CW. Early association of reactive astrocytes with senile plaques in Alzheimer’s disease. Exp Neurol. 1995;132(2):172–9.CrossRefPubMed

92.

Jha MK, Kim JH, Song GJ, Lee WH, Lee IK, Lee HW, et al. Functional dissection of astrocyte-secreted proteins: implications in brain health and diseases. Prog Neurobiol. 2018;162:37–69. https://doi.org/10.1016/j.pneurobio.2017.12.003.CrossRefPubMed

93.

Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer’s disease. Neurobiol Aging. 2003;24(2):321–31.CrossRefPubMed

94.

Simpson JE, Ince PG, Haynes LJ, Theaker R, Gelsthorpe C, Baxter L, et al. Population variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer-type pathology in the ageing brain. Neuropathol Appl Neurobiol. 2010;36(1):25–40. https://doi.org/10.1111/j.1365-2990.2009.01030.x.CrossRefPubMed

95.

Serrano-Pozo A, Gomez-Isla T, Growdon JH, Frosch MP, Hyman BT. A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am J Pathol. 2013

96.

Marlatt MW, Bauer J, Aronica E, van Haastert ES, Hoozemans JJ, Joels M, et al. Proliferation in the Alzheimer hippocampus is due to microglia, not astroglia, and occurs at sites of amyloid deposition. Neural Plast. 2014;2014:693851. https://doi.org/10.1155/2014/693851.CrossRefPubMedPubMedCentral

97.

De Strooper B, Karran E. The cellular phase of Alzheimer’s disease. Cell. 2016;164(4):603–15. https://doi.org/10.1016/j.cell.2015.12.056.CrossRefPubMed

98.

Ekblom J, Jossan SS, Bergstrom M, Oreland L, Walum E, Aquilonius SM. Monoamine oxidase-B in astrocytes. Glia. 1993;8(2):122–32. https://doi.org/10.1002/glia.440080208.CrossRefPubMed

99.

Ekblom J, Jossan SS, Oreland L, Walum E, Aquilonius SM. Reactive gliosis and monoamine oxidase B. J Neural Transm Suppl. 1994;41:253–8.PubMed

100.

Jossan SS, Ekblom J, Aquilonius SM, Oreland L. Monoamine oxidase-B in motor cortex and spinal cord in amyotrophic lateral sclerosis studied by quantitative autoradiography. J Neural Transm Suppl. 1994;41:243–8.PubMed

101.

Tong J, Rathitharan G, Meyer JH, Furukawa Y, Ang LC, Boileau I, et al. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders. Brain. 2017;140(9):2460–74. https://doi.org/10.1093/brain/awx172.CrossRefPubMedPubMedCentral

102.

Gulyas B, Pavlova E, Kasa P, Gulya K, Bakota L, Varszegi S, et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int. 2011;58(1):60–8. https://doi.org/10.1016/j.neuint.2010.10.013.CrossRefPubMed

103.

Marutle A, Gillberg PG, Bergfors A, Yu W, Ni R, Nennesmo I, et al. (3)H-deprenyl and (3)H-PIB autoradiography show different laminar distributions of astroglia and fibrillar beta-amyloid in Alzheimer brain. J Neuroinflammation. 2013;10:90. https://doi.org/10.1186/1742-2094-10-90.CrossRefPubMedPubMedCentral

104.

Lemoine L, Saint-Aubert L, Nennesmo I, Gillberg PG, Nordberg A. Cortical laminar tau deposits and activated astrocytes in Alzheimer’s disease visualised by 3H-THK5117 and 3H-deprenyl autoradiography. Sci Rep. 2017;7:45496. https://doi.org/10.1038/srep45496.CrossRefPubMedPubMedCentral

105.

Santillo AF, Gambini JP, Lannfelt L, Langstrom B, Ulla-Marja L, Kilander L, et al. In vivo imaging of astrocytosis in Alzheimer’s disease: an (1)(1)C-L-deuteriodeprenyl and PIB PET study. Eur J Nucl Med Mol Imaging. 2011;38(12):2202–8. https://doi.org/10.1007/s00259-011-1895-9.CrossRefPubMed

106.

Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nuclear Med : official publication, Society of Nuclear Medicine. 2012;53(1):37–46. https://doi.org/10.2967/jnumed.110.087031.CrossRef

107.

Johansson A, Engler H, Blomquist G, Scott B, Wall A, Aquilonius SM, et al. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J Neurol Sci. 2007;255(1–2):17–22. https://doi.org/10.1016/j.jns.2007.01.057.CrossRefPubMed

108.

Engler H, Nennesmo I, Kumlien E, Gambini JP, Lundberg P, Savitcheva I, et al. Imaging astrocytosis with PET in Creutzfeldt-Jakob disease: case report with histopathological findings. Int J Clin Exp Med. 2012;5(2):201–7.PubMedPubMedCentral

109.

Scholl M, Carter SF, Westman E, Rodriguez-Vieitez E, Almkvist O, Thordardottir S, et al. Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography. Sci Rep. 2015;5:16404. https://doi.org/10.1038/srep16404.CrossRefPubMedPubMedCentral

110.

Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Scholl M, et al. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease. Brain J Neurol. 2016;139(Pt 3):922–36. https://doi.org/10.1093/brain/awv404.CrossRef

111.

Rodriguez-Vieitez E, Ni R, Gulyas B, Toth M, Haggkvist J, Halldin C, et al. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. Eur J Nucl Med Mol Imaging. 2015;42(7):1119–32. https://doi.org/10.1007/s00259-015-3047-0.CrossRefPubMedPubMedCentral

112.

Regunathan S, Feinstein DL, Reis DJ. Expression of non-adrenergic imidazoline sites in rat cerebral cortical astrocytes. J Neurosci Res. 1993;34(6):681–8. https://doi.org/10.1002/jnr.490340611.CrossRefPubMed

113.

Olmos G, Alemany R, Escriba PV, Garcia-Sevilla JA. The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain. Br J Pharmacol. 1994;111(4):997–1002. https://doi.org/10.1111/j.1476-5381.1994.tb14842.x.CrossRefPubMedPubMedCentral

114.

Garcia-Sevilla JA, Escriba PV, Guimon J. Imidazoline receptors and human brain disorders. Ann N Y Acad Sci. 1999;881:392–409.CrossRefPubMed

115.

Tyacke RJ, Fisher A, Robinson ES, Grundt P, Turner EM, Husbands SM, et al. Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-dihydro-1H-imidazol-2-yl)-1- methyl-1H-indole), for the imidazoline(2) binding site. Synapse. 2012;66(6):542–51. https://doi.org/10.1002/syn.21541.CrossRefPubMed

116.

Kealey S, Turner EM, Husbands SM, Salinas CA, Jakobsen S, Tyacke RJ, et al. Imaging imidazoline-I2 binding sites in porcine brain using 11C-BU99008. J Nuclear Med : official publication, Society of Nuclear Medicine. 2013;54(1):139–44. https://doi.org/10.2967/jnumed.112.108258.CrossRef

117.

Parker CA, Nabulsi N, Holden D, Lin SF, Cass T, Labaree D, et al. Evaluation of 11C-BU99008, a PET ligand for the imidazoline2 binding sites in rhesus brain. J Nuclear Med: official publication, Society of Nuclear Medicine. 2014;55(5):838–44. https://doi.org/10.2967/jnumed.113.131854.CrossRef

118.

Tyacke RJ, Myers JFM, Venkataraman A, Mick I, Turton S, Passchier J, et al. Evaluation of (11)C-BU99008, a positron emission tomography ligand for the Imidazoline2 binding site in human brain. J Nuclear Med : official publication, Society of Nuclear Medicine. 2018. https://doi.org/10.2967/jnumed.118.208009.CrossRefPubMed

119.

Fan Z, Calsolaro V, Mayers J, Tyacke R, Venkataraman A, Femminella GD, et al. Relationship between astrocyte activation using [11C]BU99008 PET, glucose metabolism and amyloid in Alzheimer’s disease: a dementia platform UK experimental medicine study. Alzheimers Dement. 2018;14(7):P1640. https://doi.org/10.1016/j.jalz.2018.06.2999.CrossRef

120.

Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim HI, et al. [18F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. 2017;20(3):393–5. https://doi.org/10.1038/nn.4492.CrossRefPubMedPubMedCentral

121.

Magistretti PJ, Pellerin L. The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies. Mol Psychiatry. 1996;1(6):445–52.PubMed

122.

Pellerin L, Pellegri G, Bittar PG, Charnay Y, Bouras C, Martin JL, et al. Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle. Dev Neurosci. 1998;20(4–5):291–9. https://doi.org/10.1159/000017324.CrossRefPubMed

123.

Carter SF, Chiotis K, Nordberg A, Rodriguez-Vieitez E. Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2019;46(2):348–56. https://doi.org/10.1007/s00259-018-4217-7.CrossRefPubMed

124.

Acosta C, Anderson HD, Anderson CM. Astrocyte dysfunction in Alzheimer disease. J Neurosci Res. 2017. https://doi.org/10.1002/jnr.24075.CrossRefPubMed

125.

Hefendehl JK, LeDue J, Ko RW, Mahler J, Murphy TH, MacVicar BA. Mapping synaptic glutamate transporter dysfunction in vivo to regions surrounding Abeta plaques by iGluSnFR two-photon imaging. Nat Commun. 2016;7:13441. https://doi.org/10.1038/ncomms13441.CrossRefPubMedPubMedCentral

126.

Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer’s disease. Ann Neurol. 1996;40(5):759–66. https://doi.org/10.1002/ana.410400512.CrossRefPubMed

127.

Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ. Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer’s disease mouse model: mechanism for deficient glutamatergic transmission? Mol Neurodegener. 2011;6:55. https://doi.org/10.1186/1750-1326-6-55.CrossRefPubMedPubMedCentral

128.

Pascual JM, Van Heertum RL, Wang D, Engelstad K, De Vivo DC. Imaging the metabolic footprint of Glut1 deficiency on the brain. Ann Neurol. 2002;52(4):458–64. https://doi.org/10.1002/ana.10311.CrossRefPubMed

129.

Vlassenko AG, Gordon BA, Goyal MS, Su Y, Blazey TM, Durbin TJ, et al. Aerobic glycolysis and tau deposition in preclinical Alzheimer’s disease. Neurobiol Aging. 2018;67:95–8. https://doi.org/10.1016/j.neurobiolaging.2018.03.014.CrossRefPubMedPubMedCentral

130.

Montal V, Vilaplana E, Alcolea D, Pegueroles J, Pasternak O, Gonzalez-Ortiz S, et al. Cortical microstructural changes along the Alzheimer’s disease continuum. Alzheimers Dement. 2018;14(3):340–51. https://doi.org/10.1016/j.jalz.2017.09.013.CrossRefPubMed

131.

Femminella GD, Dani M, Wood M, Fan Z, Calsolaro V, Atkinson R, et al. Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. Neurology. 2019;92(12):e1331–e43. https://doi.org/10.1212/WNL.0000000000007133.CrossRefPubMedPubMedCentral

132.

Wang Q, Wang Y, Liu J, Sutphen CL, Cruchaga C, Blazey T, et al. Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer’s disease. Neuroimage Clin. 2019;22:101767. https://doi.org/10.1016/j.nicl.2019.101767.CrossRefPubMedPubMedCentral

133.

Park J, Wetzel I, Marriott I, Dreau D, D’Avanzo C, Kim DY, et al. A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer’s disease. Nat Neurosci. 2018;21(7):941–51. https://doi.org/10.1038/s41593-018-0175-4.CrossRefPubMedPubMedCentral

134.

Sosna J, Philipp S, Albay R 3rd, Reyes-Ruiz JM, Baglietto-Vargas D, LaFerla FM, et al. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease. Mol Neurodegener. 2018;13(1):11. https://doi.org/10.1186/s13024-018-0244-x.CrossRefPubMedPubMedCentral

135.

Terada T, Yokokura M, Obi T, Bunai T, Yoshikawa E, Ando I, et al. In vivo direct relation of tau pathology with neuroinflammation in early Alzheimer’s disease. J Neurol. 2019. https://doi.org/10.1007/s00415-019-09400-2.CrossRefPubMed

136.

Parbo P, Ismail R, Sommerauer M, Stokholm MG, Hansen AK, Hansen KV, et al. Does inflammation precede tau aggregation in early Alzheimer’s disease? A PET study Neurobiol Dis. 2018;117:211–6. https://doi.org/10.1016/j.nbd.2018.06.004.CrossRefPubMed

137.

Dani M, Wood M, Mizoguchi R, Fan Z, Walker Z, Morgan R, et al. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer’s disease. Brain. 2018;141(9):2740–54. https://doi.org/10.1093/brain/awy188.CrossRefPubMed

138.

Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, San Martin-Paniello C, Clarimon J, Belbin O, et al. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies. J Neuroinflammation. 2017;14(1):118. https://doi.org/10.1186/s12974-017-0893-7.CrossRefPubMedPubMedCentral

139.

Falcon C, Monte-Rubio GC, Grau-Rivera O, Suarez-Calvet M, Sanchez-Valle R, Rami L, et al. CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. Neuroimage Clin. 2019;23:101801. https://doi.org/10.1016/j.nicl.2019.101801.CrossRefPubMedPubMedCentral

140.

Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91(9):e867–e77. https://doi.org/10.1212/WNL.0000000000006082.CrossRefPubMedPubMedCentral

141.

Mattsson N, Carrillo MC, Dean RA, Devous MD Sr, Nikolcheva T, Pesini P, et al. Revolutionizing Alzheimer’s disease and clinical trials through biomarkers. Alzheimers Dement (Amst). 2015;1(4):412–9. https://doi.org/10.1016/j.dadm.2015.09.001.CrossRef

142.

Boche D, Nicoll JA. Neuroinflammation in ageing and in neurodegenerative disease. Neuropathol Appl Neurobiol. 2013;39(1):1–2. https://doi.org/10.1111/nan.12009 CrossRefPubMed

143.

Satoh J, Kino Y, Asahina N, Takitani M, Miyoshi J, Ishida T, Saito Y. TMEM119 marks a subset of microglia in the human brain. Neuropathology 2016;36:39–49. https://doi.org/10.1111/neup.12235 CrossRefPubMed

Title: Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer’s disease
Authors: Delphine Boche
Alexander Gerhard
Elena Rodriguez-Vieitez
on behalf of the MINC Faculty
Publication date: 01-12-2019
Publisher: Springer Berlin Heidelberg
Keywords: Magnetic Resonance Imaging
Magnetic Resonance Imaging
Alzheimer's Disease
Alzheimer's Disease
Mild Cognitive Impairment
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 13/2019
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04462-w

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer’s disease

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 13/2019

What can artificial intelligence teach us about the molecular mechanisms underlying disease?

Artificial intelligence and radiomics in nuclear medicine: potentials and challenges

Quantitative imaging biomarkers in nuclear medicine: from SUV to image mining studies. Highlights from annals of nuclear medicine 2018

Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma

Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT

Connectomics and molecular imaging in neurodegeneration